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a-Synuclein oligomers are crucial players in the pathogenesis of Parkinson's disease. Some mechanisms involved in a-synuclein oligomer detrimental effects include membrane damage, neuroinflammation and protein-protein interactions. Recently, the cellular prion protein (PrP C ) emerged as an interactor of a-synuclein oligomers, apparently mediating their detrimental activities. Through direct in vivo and in vitro approaches we herein investigated the existence of a direct cross-talk between a-synuclein oligomers and PrP C . In vitro, we assessed a-synuclein oligomer toxicity by comparing the effect in Prnp + / + versus PrP C knockout (Prnp 0/0 ) hippocampal neurons. Through an in vivo acute mouse model, where a-synuclein oligomers injected intracerebroventricularly induce memory impairment and neuroinflammation, we verified whether these detrimental effects were preserved in Prnp 0/0 mice.
In addition, PrP C -a-synuclein oligomer direct binding was investigated through surface plasmon resonance. We found that PrP C was not mandatory to mediate a-synuclein oligomer detrimental effects in vitro or in vivo. (Forloni et al., 2016) . Parkinson's and Alzheimer's diseases are both characterized by cognitive dysfunctions mainly ascribed to these oligomeric species rather than to larger aggregates (Balducci et al., 2010 (Balducci et al., , 2017 Winner et al., 2011; Diogenes et al., 2012; La Vitola et al., 2018) . According to 'the oligomer hypothesis', there is evidence that a single intracerebroventricular (ICV) injection of -synOs and AbOs impairs new memory establishment in C57BL/6 naïve mice (Cleary et al., 2005; Balducci et al., 2010 Balducci et al., , 2017 La Vitola et al., 2018) . Several mechanisms are proposed to explain how oligomers induce cellular dysfunction and/or death: (i) alterations in membrane permeability (Tsigelny et al., 2012; Fernandez-Perez et al., 2016) ; (ii) neuroinflammation (Balducci et al., 2017; La Vitola et al., 2018) ; and (iii) protein-protein interaction (Benilova et al., 2012) . These observations have introduced the term 'oligomeropathies' (Forloni et al., 2016) for defining these disorders and have provided a new experimental paradigm for investigating Parkinson's and Alzheimer's disease pathogenesis. An emerging oligomer-protein interactor is the cellular prion protein (PrP C ), described initially as the mediator of AbOs detrimental effects and recently of -synOs (Lauren et al., 2009; Ferreira et al., 2017) . Although several studies have confirmed PrP C -AbO binding (Lauren et al., 2009; Um et al., 2012; Fluharty et al., 2013) , the functional consequences remain controversial (Balducci et al., 2010; Forloni and Balducci, 2011) . This discrepancy may arise from the co-existence of both PrP C -dependent and PrP C -independent neuropathological mechanisms hypothesized for AbO neurotoxicity (Purro et al., 2018) , which might be attributable to the action of different AbO conformers.
Recently, Ferreira et al. (2017) , exploiting indirect approaches, reported that PrP C may associate withsynOs, contributing to their deleterious effects. They demonstrated the involvement of PrP C --synO interaction in the induction of cognitive deficits in a Parkinson's disease transgenic mouse model. Through in vitro and ex vivo approaches they proved a PrP C -dependent inhibition of long-term synaptic potentiation, accompanied by an increase in Ca 2 + levels in primary neurons upon -synO exposure (Ferreira et al., 2017) .
To confirm these data using direct approaches, we compared in vitro the toxicity of -synOs in either Prnp + / + or Prnp knockout (Prnp 0/0 ) primary hippocampal neurons. In vivo we exploited an acute mouse model that we recently developed (La Vitola et al., 2018) , where a single ICV injection of well characterized -synO solutions in C57BL/6 naïve mice (Prnp + / + ) impairs recognition memory in association with hippocampal gliosis (La Vitola et al., 2018) . Through this model we could compare the effects of -synOs in both Prnp + / + and Prnp 0/0 mice. Furthermore, at molecular level, we verified the existence of a direct binding between -synO and PrP C by surface plasmon resonance (SPR), using the same approach described for the investigation of AbO-PrP C interaction (Balducci et al., 2010) . a-Synuclein oligomer preparation -SynOs were obtained by incubation of endotoxin free recombinant human -synuclein monomers from Escherichia coli cells (Caldinelli et al., 2013; La Vitola et al., 2018) . Briefly -synuclein monomers were incubated for 48 h at 37 C without shaking at 241 mM in 50 mM filtered phosphate buffer (PBS) pH 7.4. The characterization of our oligomer preparations (1, 5 and 10 mM) was obtained through atomic force microscopy and western blotting. Further details are provided in the Supplementary material.
Materials and methods Mice

Intracerebroventricular incannulation
Prnp + / + and Prnp 0/0 mice were ICV incannulated as previously described (Balducci et al., 2010) and detailed in the Supplementary material.
a-Synuclein oligomers and vehicle intracerebroventricular injection
-SynOs (1 mM/7.5 ml) or 7.5ml vehicle (PBS 50 mM pH 7.4) were ICV injected as detailed in the Supplementary material.
Novel object recognition task
Mice (eight/group) were tested in an open-square grey arena (40 Â 40 cm), 30-cm high. Memory was expressed as a discrimination index [DI = (seconds on novel À seconds on familiar) / total investigation time]. Animals with memory impairment spent the same time in the investigation the familiar and the novel object giving a lower discrimination index compared to animals without memory impairment.
Further details in can be found in the Supplementary material.
Immunohistochemistry
Immunohistochemistry analyses of the astroglial marker (GFAP) and the microglial marker (IBA1) has been investigated as previously described (La Vitola et al., 2018) .
Briefly, coronal brain slices (three/mouse) were incubated with mouse anti-GFAP antibody (1:3500, Millipore) or rabbit anti-IBA1 antibody (1:1000; Wako) at 4 C overnight. After incubation with the anti-mouse biotinylated secondary antibody (1:200; Vector Laboratories; 1 h room temperature) or the anti-rabbit biotinylated secondary antibody (1:200; Vector Laboratories; 1 h room temperature). Further details can be found in the Supplementary material.
Hippocampal neuron cultures and determination of a-synuclein oligomer toxicity
Hippocampal neurons were prepared as detailed in the Supplementary material. Twelve days from plating, neurons were treated with -synOs at 1, 5 or 10 mM and 48 h after treatment cell survival was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Further details can be found in the Supplementary material.
In vitro binding studies with surface plasmon resonance -Synuclein monomers, -synOs or Ab 1-42 Os (Stravalaci et al., 2012) were injected over the surfaces exposing PrP C captured by 3F4 or 94B4, or those coated with 3F4 or 94B4 alone (without PrP C , used for reference). Assays were performed at 25 C. The -synuclein or amyloid-b-dependent signals on the surfaces immobilizing PrP C were obtained by double referencing, subtracting the response observed on surfaces immobilizing the antibodies alone, and the signal observed injecting the vehicle alone (which allows correction for binding-independent responses, e.g. drift effects). Details can be found in the Supplementary material.
Statistical analysis
Data were analysed using the GraphPad Prism 6.0 software. Two-way analyses of variance (ANOVA) were used for the MTT assay, novel object recognition task and histology. In the presence of a significant effect of treatment the Tukey's post hoc tests was applied.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results a-Synuclein oligomer-mediated detrimental effects are PrP C -independent
To address PrP C involvement in mediating -synO toxicity in vitro, we measured the survival of Prnp + / + or Prnp 0/0 primary hippocampal neurons 48 h after exposure to 1, 5 and 10 mM -synOs. To ascertain the presence of -synOs we previously characterized our preparation through atomic force microscopy and western blotting ( Supplementary Fig. 1 ).
We found that for both genotypes, -synO toxicity was significant and comparable at all treatment conditions (Fig. 1A) . Indeed, a two-way ANOVA showed a significant effect of -synOs [F(3,46) = 24.7; P 5 0.0001] but a not significant interaction -synOs Â genotype [F(3,46) = 0.70; P = 0.56], thus indicating that -synO toxicity in this context is independent of PrP C . To investigate whether -synO detrimental effects are PrP C -mediated, we assessed memory performance in both Prnp 0/0 and Prnp + / + mice ICV injected with vehicle orsynOs (1 mM/7.5 ml). Long-term memory was evaluated in the novel object recognition task (La Vitola et al., 2018) . As shown in Fig. 1B both Prnp + / + and Prnp 0/0 mice display a significant memory impairment after ICV treatment with -synOs compared to mice receiving vehicle. This evidence suggests that also at functional level -synOs act independently of PrP C . Indeed, a two-way ANOVA showed a significant effect of -synOs [F(1,28) = 24.89; P 5 0.0001], but a not significant interaction -synOs Â genotype [F(1,28) = 0.003; P = 0.96].
Since we recently demonstrated that the memory damage induced by -synOs in our acute mouse model is associated with transient hippocampal gliosis (La Vitola et al., 2018) , we investigated whether this also occurred in Prnp 0/0 mice. By histological analysis of astrocytes (GFAP) and microglia (IBA1), we measured the extent of glial activation 4 h after treatment. This time point was selected based on previous data, which indicated thatsynO-mediated gliosis reaches its maximum expression 4 h after ICV injection (La Vitola et al., 2018) . Figure 2A and B show that -synOs led to an increase in GFAP and IBA1 expression in both Prnp + / + and Prnp 0/0 mice compared to mice receiving vehicle ( Fig. 2A and B) ; this was confirmed through a quantitative analysis (Fig. 2C and D) . Two-way ANOVA indicated a significant effect of -synOs [GFAP: Surface plasmon resonance did not reveal a direct binding between a-synuclein oligomers and PrP C To investigate PrP C --synO direct binding, we exploited SPR (Stravalaci et al., 2012) . PrP C from mouse brain homogenates was captured on SPR sensor chips coated with 3F4 or 94B4, two anti-PrP C antibodies whose epitopes lie within regions 106-111 and 186-193, respectively. We had previously verified that the captured protein is actually PrP C , as no capture was detected when flowing brain homogenate from Prnp 0/0 mice (Balducci et al., 2010) . We further ascertained that PrP C captured by both 94B4 and 3F4 retained its ability to bind 6D11, an anti-PrP C antibody directed against the same region (93-109), thought to be involved in -synO-induced toxic effects (Ferreira et al., 2017) . Under all these well-established conditions, no -synOPrP C binding was observed when well characterizedsynOs (La Vitola et al., 2018) (1 and 10 mM) were flowed over captured PrP C (Fig. 3A and B) or when injecting -synuclein monomers or -synuclein solutions incubated for 2, 6, 24, and 96 h (data not shown). In contrast, 1 mM AbOs, injected in parallel as positive controls, produced the expected binding signals (Fig. 3A and B) (Stravalaci et al., 2012) . Ferreira et al. (2017) proposed PrP C as a novel interactor of -synOs, which is apparently implicated in mediating their detrimental activities, thereby opening new perspectives to investigate -synO mechanisms of action. In the present study we investigated this emerging hypothesis further through direct in vitro and in vivo approaches. Notably, our SPR analysis did not confirm the existence of PrP C --synO binding. Moreover, -synOs impaired mouse memory and induced gliosis either in absence or in presence of PrP C . Our data contrast with those of Ferreira et al. (2017) , and although we have no explanation for this at the moment, it could be argued that different -synO preparations were used. However, in our SPR experiments, binding between PrP C and -synOs was not detected even using -synOs obtained after different times of incubation. One possible explanation is that other -synO conformers might associate with PrP C , and that both PrP C -dependent and PrP C -independent pathways may co-exist in Parkinson's disease. Further investigation is needed to clarify this -synO-PrP C interaction hypothesis to define the actual neuropathological meaning of this association. 
